Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]ZSP1273 in Healthy Chinese Participants
NCT05873426Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anlatrelvir in Influenza A (IAV), sponsored by Raynovent Biotech. Primary endpoints: Total radioactivity in plasma PK: Maximum Plasma Concentration up to 14 days, Total radioactivity in plasma PK: Area Under the Curve from time 0 to last quantifiable concentration up to 14 days and 3 more. Started Mar 2023; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT05873426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873426.